Labcorp (LH) Stock
Large clinical lab serving hospitals and drug developers. Here's the price, business snapshot, and what's worth knowing about Labcorp in August 2026.
Laboratory Corp. of America Holdings (LabCorp, ticker LH) is a large clinical diagnostics and healthcare services company providing laboratory testing, diagnostic information, and drug development services to hospitals, physicians and biopharma clients. With a market capitalisation of about $23.6bn, LabCorp earns revenue from fee-for-service testing, contracts with healthcare providers, and outsourced clinical trial services. Key investor considerations include steady structural demand for diagnostics from an ageing population and growing use of personalised medicine, balanced against sensitivity to reimbursement rates, regulatory change and competition. LabCorp’s results can be cyclical—volumes often fluctuate with public-health trends such as respiratory outbreaks—and capital allocation choices and acquisitions affect near-term profitability. Investors should review recent financials, margins, cash flow and valuation, and consider exposure to healthcare reimbursement risk. This information is educational only and not personal financial advice; investors should assess suitability and consult a professional before acting.
Why It’s Moving
Labcorp stays near record territory as oncology momentum and a fresh dividend keep investors engaged
- Labcorp shares have been drifting near record highs after a run of oncology-diagnostics wins, which is helping investors focus on growth beyond the company’s core testing business.
- The board’s newly declared $0.72 quarterly dividend adds a steady-income angle and underscores confidence in cash generation.
- A scheduled Investor Day on September 10 is keeping attention on management’s strategy, while recent analyst commentary has stayed constructive with a moderate-buy leaning.
Labcorp stays near record territory as oncology momentum and a fresh dividend keep investors engaged
- Labcorp shares have been drifting near record highs after a run of oncology-diagnostics wins, which is helping investors focus on growth beyond the company’s core testing business.
- The board’s newly declared $0.72 quarterly dividend adds a steady-income angle and underscores confidence in cash generation.
- A scheduled Investor Day on September 10 is keeping attention on management’s strategy, while recent analyst commentary has stayed constructive with a moderate-buy leaning.
Sixth Month Growth Performance
When is the next earnings date for LABCORP HOLDINGS INC (LH)?
Labcorp’s next earnings date is expected on October 27, 2026, and it would cover Q3 2026 results. This date is based on the company’s usual reporting pattern and the current earnings calendar estimates. If the company confirms a different schedule, the release could shift slightly.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Laboratory Corp. of America Holdings stock, expecting its value to rise.
Financial Health
Laboratory Corp. is performing well with solid profits, cash flow, and revenue generation.
Dividend
Laboratory Corp. of America Holdings has a low dividend yield of 1.14%, making it less attractive for dividend-focused investors. If you invested $1000 you would be paid $11.40 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Diagnostics demand trends
Ageing populations and personalised medicine support long-term demand for testing, though volumes can fluctuate with public-health events and policy changes.
Global service footprint
A broad geographic presence and biopharma contracts diversify revenue, but differing regulations and reimbursement rules across markets add complexity.
Innovation and services
Investments in technology and clinical-trial services may improve margins over time, although competition and pricing pressure can constrain gains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
